Bibliothek

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    Digitale Medien
    Digitale Medien
    Springer
    European journal of clinical pharmacology 50 (1996), S. 381-384 
    ISSN: 1432-1041
    Schlagwort(e): Key words Cicletanine ; Tolbutamide; drug interaction ; healthy volunteers
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Chemie und Pharmazie , Medizin
    Notizen: Abstract Objective: To determine the possible interaction between the antihypertensive agent cicletanine and the hypoglycaemic drug tolbutamide. Methods: Time-courses of glycaemia and serum immunoreactive insulin (IRI) were followed in 10 healthy subjects after two tolbutamide infusions in each volunteer: initially alone and 9 days later concomitantly with repeated oral cicletanine. Any drug interaction was quantified on the basis of a decrease or increase in the AUC with time of glycaemia and IRI by subtraction of baseline concentration (AUC0 240-GLY and AUC0 60-IRI). Peak glycaemia and peak IRI, and the corresponding time to peaks, were also assessed. Results: Following tolbutamide, mean AUC0 240-GLY values were 97.7 and 98.8 mmol⋅l−1⋅min, without or with cicletanine, respectively; the corresponding AUC0 60-IRI were 485 and 321 mU⋅l−1⋅min. Mean peak glycaemia values were 0.996 and 1.071 mmol⋅l−1. Regarding the peak IRI, a decrease was observed after tolbutamide and cicletanine: median values were 29.2 and 17.4 mU⋅l−1. The corresponding median time to peak of glycaemia and IRI values were 30 and 30 min, and 5 (all subjects) and 5 min. Conclusion: No clinically relevant interaction was shown after the concomitant administration of repeated oral doses of cicletanine and acute intravenous tolbutamide to healthy volunteers.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...